Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4438450 | 0.89 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1KDM2BCNR1 | |
| SCHEMBL4430354 | 0.84 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1KDM2BNAMPT | |
| SCHEMBL4431692 | 0.83 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1KDM2BNAMPT | |
| SCHEMBL4529122 | 0.83 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1KDM2BALDH1A1NAMPT | |
| SCHEMBL4523703 | 0.82 | L3MBTL3 (0.48) | PRMT5WDR77L3MBTL3L3MBTL1KDM2B | |
| SCHEMBL4530572 | 0.82 | PDE4B (0.52) | L3MBTL3L3MBTL1ALDH1A1KMT2ANAMPT | |
| SCHEMBL4431810 | 0.82 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1KDM2BMEN1ALDH1A1 | |
| SCHEMBL4519212 | 0.82 | HPGD (0.55) | KDM2BCNR1ALDH1A1HPGD | |
| SCHEMBL4430623 | 0.81 | ALDH1A1 (0.53) | L3MBTL3L3MBTL1MEN1ALDH1A1HPGD | |
| SCHEMBL1017674 | 0.80 | KDM2B (0.44) | PRMT5WDR77L3MBTL3L3MBTL1KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125741-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | claimed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | claimed |
| WO-2008109336-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | claimed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008109336-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | PRMT5 482/4885WDR77 592/4885L3MBTL3 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.